Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Bivalent Vaccine V-01D-351 as a Booster
NCT05583357Phase 1Unknown
- Sponsor
- Livzon Pharmaceutical Group Inc.
- Start
- Aug 2022
- Primary completion
- Sep 2022
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of V-01D-351 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Livzon Pharmaceutical Group Inc. Primary endpoint: Neutralizing antibody Geometric Mean Titer of Omicron BA.5 at 28 days. Status: unknown.
02
Drugs
V-01D-351
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05583357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05583357.